Testing additivity of anticancer agents in pre-clinical studies: A PK/PD modelling approach

European Journal of Cancer

Volumn 45, Issue 18, 2009, Pages 3336-3346

  Rocchetti, M ^a   Del Bene, F ^a   Germani, M ^a   Fiorentini, F ^a   Poggesi, I ^a,b   Pesenti, E ^c   Magni, P ^d   De Nicolao, G ^d  

^a Accelera   (Italy)

^b GSK   (Italy)

^c NERVIANO MEDICAL SCIENCES   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

Anticancer activity of combination regimens; Combination studies; Drug additivity; Drug development; Drug interaction; Mathematical model; PK PD model; Quantification of combined drug effect; Tumour growth inhibition model; Xenograft mice

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GEMCITABINE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG POTENTIATION; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; STATISTICAL MODEL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; MICE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70450250213     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.09.025     Document Type: Article

References (37)

1. De Vita VT. Principles of cancer management: chemotherapy. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Lippincott-Raven; 1997. p. 335-36.
2. Greco W.R., Bravo G., and Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47 (1995) 331-385
3. Chou T., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
4. Tallarida R.J. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319 (2006) 1-7
5. Tallarida R.J. Interactions between drugs and occupied receptors. Pharmacol Ther 113 1 (2007) 197-209
6. Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., and Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17 (1998) 2235-2249
7. Wu C.H., Wu C.C., and Ho Y.S. Antitumor activity of combination treatment of lentinus edodes mycelium extracts with 5-fluorouracil against human colon cancer cells xenografted in nude mice. J Cancer Mol 3 1 (2007) 15-22
8. Jonker D.M., Visser S.A.G., van der Graaf P.H., Voskuyl R.A., and Danhof M. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther 106 (2005) 1-18
9. Kong M., and Lee J.J. A semiparametric response surface model for assessing drug interaction. Biometrics 64 2 (2008) 396-405
10. Prichard M.N., and Shipman Jr. C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14 (1990) 181-206
11. Wild R., Fager K., Flefleh C., et al. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumour expression levels. Mol Cancer Ther 5 1 (2006) 104-113
12. Sabatino M.A., Colombo T., Geroni C., Marchini S., and Broggini M. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clin Cancer Res 9 (2003) 5402-5408
13. D'Incalci M., Colombo T., Ubezio P., et al. The combination of Yondelis and cisplatin is synergistic against human tumour xenografts. Eur J Cancer 39 (2003) 1920-1926
14. Klein M.B., Campeol N., Lalonde R.G., Brenner B., and Wainberg M.A. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS 17 (2003) 1001-1008
15. Pegram M.D., Konecny G.E., O'Callaghan C., Beryt M., Pietras R., and Slamon D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96 (2004) 739-749
16. Zhao L., Wientjes M.G., and Au J.L.-S. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10 (2004) 7994-8004
17. Warburton C., Dragowska W.H., Gelmon K., et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumour growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10 (2004) 2512-2524
18. Koizumi F., Kanzawa F., Ueda Y., et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 108 (2004) 464-472
19. Harris S.M., Mistry P., Freathy C., Brown J.L., and Charlton P.A. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. Br J Cancer 92 (2005) 722-728
20. Sadler T.M., Gavriil M., Annable T., Frost P., Greenberger L.M., and Zhang Y. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr Relat Cancer 13 (2006) 863-873
21. Menendez J.A., Mehmi I., and Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 24 (2006) 3735-3746
22. Simeoni M., Magni P., Cammia C., et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumour growth kinetics in xenograft models after administrations of anticancer agents. Cancer Res 64 (2004) 1094-1101
23. Rocchetti M., Poggesi I., Germani M., et al. A PK-PD model for predicting tumour growth inhibition in mice. a useful tool in oncology drug development. Basic Clin Pharm Toxicol 96 (2005) 265-268
24. Earp J., Krzyzanski W., Chakraborty A., Zamacona M.K., and Jusko W.J. Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokin Pharmacodyn 31 (2004) 345-380
25. Koch G., Walz A., Lahu G., and Schropp J. Modeling of tumour growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn 36 (2009) 179-197
26. Magni P., Simeoni M., Poggesi I., Rocchetti M., and De Nicolao G. A mathematical model to study the effects of drugs administration on tumour growth dynamics. Math Biosci 200 (2006) 127-151
27. Magni P., Germani M., De Nicolao G., et al. A minimal model of tumour growth inhibition. IEEE Trans Biomed Eng 55 12 (2008) 2683-2690
28. Del Bene F., Germani M., and De Nicolao G. A model-based approach to the in vitro evaluation of anticancer activity. Cancer Chem Pharmacol 63 (2009) 827-836
29. Rocchetti M., Simeoni M., Pesenti E., De Nicolao G., and Poggesi I. Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 43 (2007) 1862-1868
30. Carpinelli P., Ceruti R., Giorgini M.L., et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6 12 (2007) 3158-3168
31. Menichincheri M., Bargiotti A., Berthelsen J., et al. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. J Med Chem 52 (2009) 293-307
32. Mager D.E., and Jusko W.J. Chapter 23: Mechanistic pharmacokinetic/pharmacodynamic models II. Pharmacometrics: the science of quantitative pharmacology (2007), Wiley-Interscience ISBN: 0471677833, 9780471677833
33. Bueno L., de Alwis D., Pitou C., Yingling J., Lahn M., Glatt S., et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. Eur J Cancer 44 (2008) 142-150
34. James C.A., Breda M., Frigerio E., Long J., and Munesada K. Fast turnaround bioanalysis in discovery and early clinical development. Chromatographia 55 Suppl. (2002) S41-S43
35. Poggesi I, Simeoni M, germani M, De Nicolao G, Rocchetti M. Population modeling of tumor growth in untreated xenografted mice. PAGE 2004; 13(Abstract):535. [accessed 10.09.09].
36. Simeoni M, Poggesi I, De Nicolao G, Germani M, Rocchetti M. Population modeling of tumor growth inhibition in vivo: application to anticancer drug development. PAGE 2004;13(Abstract): 503. [accessed 10.09.09].
37. Del Bene F, Germani M, Fiorentini F, De Nicolao G, Magni P, Rocchetti M. Evaluating the influence of different sources of variability in the PK/PD tumor growth inhibition (TGI) model. PAGE (2008);17(Abstract):1431. [accessed 10.09.09].